Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis c Clear all
Not listed Not applicable Interventional

Hepatitis C Treatment in Underserved Populations

NCT01717560
View directory record Official record
Conditions
Chronic Hepatitis C, Illicit Drug Use
Interventions
Collaborative, multidisciplinary, integrated care
Other
Lead sponsor
Brian Edlin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

NCT00637923
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin
Drug · Biological
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Harvoni Treatment Porphyria Cutanea Tarda

NCT03118674
View directory record Official record
Conditions
Porphyria Cutanea Tarda, Hepatitis C
Interventions
Harvoni
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
San Francisco, California • Winston-Salem, North Carolina • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 15, 2026, 2:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

NCT01447680
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Hepatitis C
Interventions
Not listed
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Douglasville, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 1 Interventional

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

NCT00001035
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Interferon alfa-2b, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional

Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes

NCT00324389
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon alpha
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Nov 15, 2026, 2:57 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

NCT04395118
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Mailed Outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

NCT01516918
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
VX-222, telaprevir, ribavirin, peginterferon-alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • San Diego, California • Englewood, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

NCT01356160
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Nov 15, 2026, 2:57 AM EST
Completed Not applicable Interventional Results available

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

NCT03214679
View directory record Official record
Conditions
Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
Interventions
Accessible Care, Usual Care
Other
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270
View directory record Official record
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 1 Interventional

Health Behavior Feedback Study for Veterans With Hepatitis C

NCT00229580
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Hepatitis C, Liver Disease
Interventions
3 session brief intervention with health behavior feedback, treatment as usual
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2007 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 3 Interventional Results available

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT01399619
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PegIFN/RBV, BI201335, BI201335 24W, Bi 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Nov 15, 2026, 2:57 AM EST
Not listed No phase listed Observational

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 15, 2026, 2:57 AM EST
Active, not recruiting Not applicable Interventional

Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants

NCT04701437
View directory record Official record
Conditions
Hepatitis C
Interventions
Peer mentor, Standard of care
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 15, 2026, 2:57 AM EST
Completed Not applicable Interventional Results available

Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV

NCT03652675
View directory record Official record
Conditions
Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
Interventions
Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Nov 15, 2026, 2:57 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

NCT05368974
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
The Task Force for Global Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Nov 15, 2026, 2:57 AM EST
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Nov 15, 2026, 2:57 AM EST